NDT Advance Access originally published online on July 5, 2006
Nephrology Dialysis Transplantation 2006 21(9):2348-2351; doi:10.1093/ndt/gfl315
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Editorial Comment
Progression of renal diseasecan we forget about inhibition of the reninangiotensin system?
1 Department of Nephrology, Schwabing General Hospital, Ludwig Maximilian University, Germany, 2 Department of Medicine, Emory University School of Medicine, USA, 3 Institute of Clinical Epidemiology, University of Basle, Switzerland and 4 Department of Nephrology, Ruperto Carola University, Heidelberg, Germany
Correspondence and offprint requests to: Johannes F. E. Mann, MD, Schwabing General Hospital, Ludwig Maximilians University, Kolner Platz 1, Munchen 80804, Germany. Email: johannes.mann@kms.mhn.de
Keywords: ACE; antihypertensive drugs; blood pressure; progression; renal insufficiency; renin
| The first 150 words of the full text of this article appear below. |
| Introduction |
|---|
A recent meta-analysis by Casas et al. [1] concluded that ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) reduce the progression of renal events by nothing more than their blood pressure (BP)-lowering effect. Surprisingly, this meta-analysis [1] contradicts most randomized controlled trials and other meta-analyses [25] investigating the effect of inhibition of the reninangiotensin system (RAS) on the progression of chronic kidney disease. We have analysed the methodological quality of this meta-analysis and put it into perspective with other meta-analyses and large randomized controlled trials. We have come to the conclusion that there are serious problems, which undermine the conclusion drawn by Casas et al. [1].
| Data analysis by Casas et al. [1] |
|---|
How did the authors reach their surprising conclusion? Casas et al. [1] selected randomized controlled trials comparing inhibitors of the RAS with other regimens, defining the progression of renal disease as
| Blood pressure-independent nephroprotective effects of ACEI/ARB |
|---|
| The ALLHAT trap |
|---|
| ACEI/ARB not indicated in diabetic nephropathy? |
|---|
| Comparison of Casas et al. with previous meta-analyses |
|---|
| No dataProteinuria, the hallmark of renal risk |
|---|
| Lack of patient-level data |
|---|
| Conclusions |
|---|
This article has been cited by other articles:
![]() |
F. F. Hou, D. Xie, X. Zhang, P. Y. Chen, W. R. Zhang, M. Liang, Z. J. Guo, and J. P. Jiang Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: A Randomized Controlled Study of Benazepril and Losartan in Chronic Renal Insufficiency J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1889 - 1898. [Abstract] [Full Text] [PDF] |
||||
